-
Mashup Score: 0Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study - 13 day(s) ago
Objective To estimate the association between oncologists’ receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value interventions among their patients. Design Cohort study. Setting Fee-for-service Medicare claims. Participants Medicare beneficiaries with a diagnosis of incident cancer (new occurrence of a cancer diagnosis code in proximity to claims for cancer treatment, and no such diagnosis codes during a ≥1 year washout period) during 2014-19, who met additional requirements identifying them as at risk for one of four non-recommended or low value interventions: denosumab for castration sensitive prostate cancer, granulocyte colony stimulating factors (GCSF) for patients at low risk for neutropenic fever, nab-paclitaxel for cancers with no evidence of superiority over paclitaxel, and a branded drug in settings where a generic or biosimilar version was available. Main outcome measures Receipt of the non-recommended or low value drug for which t
Source: www.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Despite ongoing concerns and well-publicized scandals, financial conflict-of-interest between US physicians and the drug industry remains common. US physicia…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Study bolsters concerns about US FDA accelerated drug approvals - 13 day(s) ago
Half of the cancer drugs granted expedited approval by the US Food and Drug Administration (FDA) between 2013 and 2017 failed to show clinical benefits for patients in confirmatory trials more than 5 years later, according to a study by Liu and colleagues published in JAMA on April 7, 2024, and presented at the American Association of Cancer Research’s 2024 annual meeting. Of 39 confirmatory trials, 19 showed no overall survival or quality of life benefits for patients. Confirmatory studies had not yet been completed for seven other cancer drugs granted accelerated approval.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Study bolsters concerns about US FDA accelerated drug approvals - 13 day(s) ago
Half of the cancer drugs granted expedited approval by the US Food and Drug Administration (FDA) between 2013 and 2017 failed to show clinical benefits for patients in confirmatory trials more than 5 years later, according to a study by Liu and colleagues published in JAMA on April 7, 2024, and presented at the American Association of Cancer Research’s 2024 annual meeting. Of 39 confirmatory trials, 19 showed no overall survival or quality of life benefits for patients. Confirmatory studies had not yet been completed for seven other cancer drugs granted accelerated approval.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Study bolsters concerns about US FDA accelerated drug approvals - 14 day(s) ago
Half of the cancer drugs granted expedited approval by the US Food and Drug Administration (FDA) between 2013 and 2017 failed to show clinical benefits for patients in confirmatory trials more than 5 years later, according to a study by Liu and colleagues published in JAMA on April 7, 2024, and presented at the American Association of Cancer Research’s 2024 annual meeting. Of 39 confirmatory trials, 19 showed no overall survival or quality of life benefits for patients. Confirmatory studies had not yet been completed for seven other cancer drugs granted accelerated approval.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Industry payments appeared to have been little changed by public reporting in the Open Payments database.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Conflicts of interest in healthcare: where are we now? - 29 day(s) ago
Conflicts of interest in medicine have been a problem for decades but what are we doing about it? What evidence do we have that it is making any difference? …
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Seminar | Conflicts of interest in healthcare - where are we now - 1 month(s) ago
Conflicts of interest in healthcare: where are we now? About the Event: Conflicts of interest in medicine have been a problem for decades but what are we doing about it? What evidence do we have that it is making any difference? Are conflicts of interest in medicine destined to be a ‘forever wicked’ problem? This talk is unlikely to give any helpful answers but will try to define the problems that we (still) need answers to. About the Speaker: Dr. Margaret McCartney is a general practitioner, freelance
Source: mailchi.mpCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1ChatGPT for Automated Cross-Checking of Authors' Conflicts of Interest Against Industry Payments - PubMed - 1 month(s) ago
LLMs have robust potential to automate author-company-specific COI cross-checking against the OpenPayments database. Our findings pave the way for streamlined, efficient, and accurate COI assessment that could be widely employed across medical research.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Outside the Guidelines: Denosumab Overuse in Prostate Cancer - 2 month(s) ago
Many men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet
@bmj_latest study here: https://t.co/yYNbyiQoU2